IRCT20200408046990N5尚未招募2 期
Evaluation of oral formulation of Nano Silymarin efficacy, as an adjuvant to XELOX or FOLFOX regimen treatment for metastatic colorectal cancer: A triple blinded, randomized clinical trial
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 70 years（—）
- 性别
- All
入选标准
- •Patients with confirmed histological or cytological diagnosis of metastatic colorectal cancer (stage 4) Based on ultrasound results without NRAS and KRAS mutation or no candidate for target therapy(Contraindications or financial incapacity)
- •Under XELOX or FOLFOX regime treatment
- •Patient consent to study
- •Eastern cooperative oncology group (ECOG) 0/ 1
- •Hemoglobin=9g/dL? Neutrophil count=1.5×103/µL, Platelet count=10×104/µL
- •Creatinine=1.5 mg/dl, ALT,AST =5 ×ULN? total bilirubin=2×
排除标准
- •use of other antioxidant
- •pregnancy or lactation
- •history of allergy to formulation components
- •diagnosed with more than one cancer
- •history of HF
- •history of autoimmune or immunodeficiency (medical or drug induced) other than chemotherapy
- •history of HBV or HCV
- •candidate of curative surgery
研究者
相似试验
招募中
3 期
Evaluation of oral nano-silymarin formulation effect in prevention of liver damage induced by doxorubicin-cyclophosphamide chemotherapy regimen in patients with non-metastatic breast canceron-metastatic breast cancer.Malignant neoplasm of breastIRCT20200408046990N13Mashhad University of Medical Sciences70
招募中
3 期
Evaluating the effect of silymarin oral form on the control of liver toxicity caused by adriamycin and cyclophosphamide drugs in patients with non metastatic breast cancerIRCT2017091136125N1Vice chancellor for research, Mashhad University of Medical Sciences40
招募中
3 期
Evaluation of silymarin tablet efficacy in prevention of hepatotoxicity induced by doxorubicin containing chemotherapy regimen in patients with non-metastatic breast cancerIRCT20200408046990N6Mashhad University of Medical Sciences50
已完成
2 期
the evaluation of effectiveness of oral silymarin on memory status of patients with dementiaCondition 1: Dementia in Alzheimer disease. Condition 2: Vascular dementia. Condition 3: Dementia in other diseases classified elsewhere.Alzheimer disease is a primary degenerative cerebral disease of unknown etiology with characteristic neuropathological and neurochemical features. The disorder is usually insidious in onset and develops slowly but steadily over a period of several years.Vascular dementia is the result of infarction of the brain due to vascular disease, including hypertensive cerebrovascular disease. The infarcts are usually small but cumulative in their effect. Onset is usually in later life.Cases of dementia due, or presumed to be due, to causes other than Alzheimer disease or cerebrovascular disease. Onset may be at any time in life, though rarely in old age.IRCT201505091856N5Vice-chancellor for research, Kermanshah University of Medical Sciences100
尚未招募
3 期
Efficacy of oral silymarin formulation on prostate canceron metastatic prostate cancer.Benign neoplasm of prostateIRCT20180517039694N1Mashhad University of Medical Sciences100